Chemistry:Etuvetidigene autotemcel
| Clinical data | |
|---|---|
| Trade names | Waskyra |
| Other names | GSK-2696275, OTL-103 |
| AHFS/Drugs.com | waskyra |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| UNII | |
Etuvetidigene autotemcel, sold under the brand name Waskyra, is a gene therapy medication used for the treatment of Wiskott–Aldrich syndrome.[2][3]
The most common side effects include rash, respiratory tract infection, febrile neutropenia, catheter related infection, vomiting, diarrhea, liver injury, and petechiae.[5]
The active substance of etuvetidigene autotemcel consists of genetically modified autologous CD34+ hematopoietic stem cell enriched population transduced ex vivo with a lentiviral vector encoding the human Wiskott–Aldrich syndrome gene.[3] Etuvetidigene autotemcel is a gene therapy that inserts the Wiskott–Aldrich syndrome corrected gene into the cell's genome, making the genetically modified cells capable of expressing the functional Wiskott–Aldrich syndrome protein.[3] The genetically modified cells engraft and repopulate the hematopoietic compartment.[3] They differentiate and produce biologically active lymphoid and myeloid progenitors whose progeny express Wiskott–Aldrich syndrome protein.[3]
Etuvetidigene autotemcel was approved for medical use in the United States in December 2025,[5] and in the European Union in January 2026.[3][4]
Medical uses
Etuvetidigene autotemcel is indicated for the treatment of people with Wiskott-Aldrich syndrome who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation is appropriate and no suitable human leukocyte antigen-matched related stem cell donor is available.[2][5]
Wiskott-Aldrich syndrome is a rare, life-threatening genetic disease caused by mutations in the WAS gene.[5] The condition is characterized by bleeding, eczema, recurrent infections, and increased susceptibility to autoimmunity and lymphoreticular malignancies.[5]
Etuvetidigene autotemcel consists of the recipient's own hematopoietic (blood) stem cells, which have been genetically modified to include functional copies of the WAS gene.[5] Following reduced-intensity conditioning, the gene-corrected cells are infused intravenously to restore blood cell production.[5] Etuvetidigene autotemcel restores functional WAS protein expression in affected cells, addressing the underlying cause of the disease.[5]
History
The safety and effectiveness of etuvetidigene autotemcel was assessed based on two open-label, single-arm, multinational clinical studies and an expanded access program totaling 27 participants with severe Wiskott-Aldrich syndrome, which demonstrate substantial and sustained clinical benefit for people with severe Wiskott-Aldrich syndrome, with significant reductions in the primary disease manifestations that drive morbidity and mortality.[5]
The US Food and Drug Administration (FDA) granted the application for etuvetidigene autotemcel orphan drug, rare pediatric disease, and regenerative medicine advanced therapy designations.[5] The FDA granted approval of Waskyra to Fondazione Telethon ETS.[5] It is a first approved cell and gene therapy product from a non-profit applicant.[5]
Society and culture
Legal status
Etuvetidigene autotemcel was approved for medical use in the United States in December 2025.[5]
In November 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Waskyra, intended for the treatment of Wiskott–Aldrich syndrome.[3] The applicant for this medicinal product is Fondazione Telethon ETS.[3][6] Etuvetidigene autotemcel was authorized for medical use in the European Union in January 2026.[3][4]
Names
Etuvetidigene autotemcel is the international nonproprietary name.[7]
Etuvetidigene autotemcel is sold under the brand name Waskyra.[2][5]
References
- ↑ "Waskyra (etuvetidigene autotemcel) suspension, for intravenous use" (PDF). Fondazione Telethon ETS. December 2025. https://www.fda.gov/media/190096/download.
- ↑ 2.0 2.1 2.2 2.3 "Waskyra". 9 December 2025. https://www.fda.gov/vaccines-blood-biologics/waskyra.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 "Waskyra EPAR". 14 November 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/waskyra. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 4.0 4.1 4.2 "Waskyra Product information". 9 January 2026. https://ec.europa.eu/health/documents/community-register/html/h1996.htm.
- ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 "FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome". U.S. Food and Drug Administration (FDA) (Press release). 9 December 2025. Retrieved 11 December 2025.
This article incorporates text from this source, which is in the public domain.
- ↑ "First gene therapy to treat rare disease Wiskott-Aldrich syndrome". 14 November 2025. https://www.ema.europa.eu/en/news/first-gene-therapy-treat-rare-disease-wiskott-aldrich-syndrome. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information 36 (1). 2022.
External links
- "Etuvetidigene Autotemcel ( Code - C184832 )". https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C184832.
- Clinical trial number NCT01515462 for "Gene Therapy for Wiskott-Aldrich Syndrome (TIGET-WAS)" at ClinicalTrials.gov
- Clinical trial number NCT03837483 for "A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome" at ClinicalTrials.gov
 |  |
